Picture of Beam Therapeutics logo

BEAM Beam Therapeutics Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Momentum

Relative Strength (%)
1m+2.91%
3m+4.06%
6m+17.29%
1yr-15.91%
Volume Change (%)
10d/3m-6.88%
Price vs... (%)
52w High-32.06%
50d MA+6.54%
200d MA+20.54%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-14.07%
Return on Equity-15.46%
Operating Margin-46.73%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Beam Therapeutics EPS forecast chart

Profile Summary

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
January 25th, 2017
Public Since
February 6th, 2020
No. of Shareholders
33
No. of Employees
436
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
81,657,714
Blurred out image of a map
Address
238 Main Street, CAMBRIDGE, 02142
Web
https://beamtx.com/
Phone
+1 8573278775
Auditors
Deloitte & Touche LLP

BEAM Share Price Performance

Upcoming Events for BEAM

Q1 2024 Beam Therapeutics Inc Earnings Release

Beam Therapeutics Inc Annual Shareholders Meeting

Q2 2024 Beam Therapeutics Inc Earnings Release

Similar to BEAM

Picture of 2Seventy Bio logo

2Seventy Bio

us flag iconNASDAQ Global Select Market

Picture of 4D Molecular Therapeutics logo

4D Molecular Therapeutics

us flag iconNASDAQ Global Select Market

Picture of AbCellera Biologics logo

AbCellera Biologics

us flag iconNASDAQ Global Select Market

Picture of AbSci logo

AbSci

us flag iconNASDAQ Global Select Market

Picture of Acadia Pharmaceuticals logo

Acadia Pharmaceuticals

us flag iconNASDAQ Global Select Market

FAQ